An in-depth understanding of the pathophysiology of psoriasis led to significant advances in the development of safe and efficient novel therapeutic options, with four classes of biologic therapy being approved for the management of moderate to severe psoriasis: TNF-α inhibitors, anti-IL-23 agents, anti-IL-12/23 agents, IL-17 inhibitors, as well as small-molecule inhibitors, such as apremilast, as presented in Table 1 [26]. The gene discussed is IL17A; the disease is psoriasis.